Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection.
APX001, the prodrug of the active moiety APX001A, is currently in clinical development by Amplyx Pharmaceuticals. It works through a novel mechanism of action. Unlike other antifungal agents that poke holes in yeast cell membranes or inhibit sterol synthesis, the new drug targets an enzyme called Gwt1, which is required for anchoring critical proteins to the fungal cell wall. This means C. auris can’t grow properly and has a harder time forming drug-resistant fungal biofilms that are a stubborn source of hospital outbreaks. Gwt1 is highly conserved across fungal species, suggesting the new drug could treat a broad range of fungal infections.
“The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unlikely to have developed workarounds for its mechanism of action,” said study lead Mahmoud A. Ghannoum, PhD, professor of dermatology at Case Western Reserve University School of Medicine and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
In the new study, Ghannoum’s team tested the drug against 16 different C. auris strains, collected from infected patients in Germany, Japan, South Korea, and India. When they exposed the isolates to the new drug, they found it more potent than nine other currently available antifungals. According to the authors, the concentration of study drug needed to kill C. auris growing in laboratory dishes was “eight-fold lower than the next most active drug, anidulafungin, and more than 30-fold lower than all other compounds tested.”
The researchers also developed a new mouse model of invasive C. auris infection for the study. Said Ghannoum, “To help the discovery of effective drugs it will be necessary to have an animal model that mimics this infection. Our work helps this process in two ways: first we developed the needed animal model that mimics the infection caused by this devastating yeast, and second, we used the developed model to show the drug is effective in treating this infection.”
Ghannoum studied immunocompromised mice infected with C. auris via their tail vein—similar to very sick humans in hospitals who experience bloodstream infections. Infected mice treated with APX001 and anidulafungin had significant reductions in kidney and lung fungal burden two days post-treatment, compared to control animals. APX001 also significantly decreased fungal burden in the brain, consistent with brain penetration, whereas reduction with anidulafungin did not reach significance. The results suggest the new drug could help treat even the most invasive infections.
According to Ghannoum, the most exciting element of the study is that it brings a promising antifungal one step closer to patients. It helps lay the foundation for phase 2 clinical trials that study that study the safety and efficacy of new drugs in patients with fungal infections. There is an urgent need for such studies, as C. auris infection has become a serious threat to healthcare facilities worldwide—and resistance to commercially available antifungal drugs is rising.
“Limited treatment options calls for the development of new drugs that are effective against this devastating infection,” Ghannoum said. “We hope that we contributed in some way towards the development of new drugs.”
The Latest on: Antifungal
via Google News
The Latest on: Antifungal
- CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Updateon November 14, 2019 at 4:29 pm
The FDA further agreed that it is appropriate to submit a request for approval of Neutrolin under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD Pathway) at the time of ...
- State: 17 LI health care facilities treated patients with drug-resistant funguson November 14, 2019 at 3:36 pm
The pathogen has triggered health alarms around the globe because even the most reliable antifungal medications have had trouble stopping it from causing infections. Through Oct. 23, the New York ...
- Antifungal Treatment Market Set Astonishing Growth with Key Players Novartis, Pfizer, Sanofi-Aventison November 12, 2019 at 11:57 pm
Nov 13, 2019 (Global QYResearch via COMTEX) -- Antifungal Treatment Market 2019: This report provides a basic overview of the industry, including its definition, applications and manufacturing ...
- SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Updateon November 12, 2019 at 4:30 am
We're confident in the commercial potential of ibrexafungerp given its differentiated attributes as a new oral, non-azole antifungal and the eagerness of women with VVC and their treating physicians ...
- New diphenylphosphane derivatives of ketoconazole are promising antifungal agentson November 7, 2019 at 2:13 am
In recent times, the emergence of pathogenic fungi resistant to commonly used antifungal drugs has been occurring at unprecedented rates 1. Antifungal resistance is especially a problem with Candida ...
- Antifungal Drugs Market Growth , Leading Players and Forecast To 2023on November 7, 2019 at 12:02 am
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of ...
- Antifungal effect of starch–gellan edible coatings with thyme essential oilon November 6, 2019 at 6:01 am
Thyme essential oil (EO) was incorporated (0.25 and 0.5 g per g of polymer) directly or encapsulated in lecithin to enhance antifungal action. Coatings did not reduce weight loss or firmness changes ...
- Basilea Pharmaceutica AG: Basilea reports marketing authorization of antifungal Cresemba® in Brazilon October 29, 2019 at 4:27 pm
Before it's here, it's on the Bloomberg Terminal.
- Global Antifungal Drugs Markets, 2018 & 2019-2027on October 16, 2019 at 4:33 am
DUBLIN, Oct. 16, 2019 /PRNewswire/ -- The "Antifungal Drugs Market to 2027 - Global Analysis and Forecasts By Infection Type; Drug Type; Therapeutic Indication; Dosage form, and Geography" report has ...
via Bing News